FIG 2.

Skin accumulation of amphotericin B (AmB), 24 h after a single intravenous (i.v.) administration of 25 mg/kg AmBisome (LAmB) to CL-infected mice at different time points postinfection and controls. Drug levels were determined in the lesion (●) and healthy control skin (○) site for each animal. CL-infected mice with skin lesions were dosed with LAmB at the time when a papule, an initial nodule, or an established nodule was present on the rump (5, 10, and 20 days after L. major infection, respectively, and 15, 30, and 45 days after L. mexicana infection, respectively). Controls for skin inflammation were uninfected mice (Uninf), pseudolesion (PL; mice with carrageenan-induced inflammatory skin initial nodule), and healed lesion (HL; mice with paromomycin-cured L. major initial nodule). Data are shown as the means ± standard error of the mean (SEM) (n = 3 to 5 per group). Statistical analysis was determined with a 2-way ANOVA, followed by Šidák multiple-comparison test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.